IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations

NCT ID: NCT01588093

Last Updated: 2012-04-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-04-30
• Study Completion Date: 2011-09-30

Brief Summary

Hormonal disturbances in the GH-IGF-I axis are considered important for the deterioration of glycemic control in T1DM particularly in adolescents. In addition it may have direct implications on the development of insulin resistance and long-term complications.

The Investigators hypothesis is that low circulating IGF-I and compensatory hyper-secretion of GH, in the presence of peripheral insulin excess, results in increased local IGF-I expression explaining both the deterioration in metabolic control and the increased risk for microvascular complications. Correction of imbalance in circulating and tissue-specific levels of IGF-I could lead to both better early metabolic control and to prevention of early diabetic complications in type 1 diabetic (T1DM) patients.

Aim of the present study is to validate the microdialysis technique as a useable tool to predict local biological effects of IGF-1 and to understand the pharmacokinetics of local IGF-I actions after sc injection of Increlex in type 1 diabetic patients.

Detailed Description

Background:

In healthy subjects, the liver extracts approximately 50 % of insulin. Therefore insulin given subcutaneously results in a relative insulin deficiency in the portal circulation of the liver, and a relative insulin excess in peripheral tissues. In comparison, normal physiological delivery of insulin from the pancreas to the portal circulation, results in markedly higher hepatic insulin exposure. The importance of hepatic insulin exposure for GH induced IGF-I synthesis comes from studies demonstrating that circulating IGF-I levels can be normalized by direct portal insulin infusion (1) or nearly normalized with intra-peritoneal insulin delivery (2). Approximately 80 % of circulating IGF-I is liver derived. Whether the GH induction of IGF-I production in other tissues such as fat, muscle and the growth plate is also insulin dependent has not been studied in humans. While locally produced IGF-I is important for linear growth, circulating IGF-I is essential for insulin sensitivity (3). Portal insulin deficiency results in uncoupling of GH induced IGF-I synthesis and subnormal circulating IGF-I levels in T1DM children with conventional therapy (4).

In newly diagnosed T1DM subcutaneous insulin treatment increases circulating IGF-I (5). The beneficial effects of 12 weeks adjuvant IGF-I treatment on metabolic control was demonstrated in conventionally insulin treated T1DM adolescents (6). There is also strong evidence for the role of IGF-I in the pathogenesis of diabetic kidney disease, atherosclerosis and proliferative retinopathy (7, 8, 9).

Interestingly, recent reports suggest an important role of IGF-I in stimulating beta cell regeneration (10). Thus a role for improvement of IGF-I in prolonging endogenous insulin secretion in the early phase of T1DM disease appears promising.

The Investigators have previously developed a microdialysis approach to measure local IGF-I protein levels from the human muscle tissue. The Investigators were in that study able to show that exercise increases local IGF-I levels. (11, 12) However, no further analysis concerning tissue-specific glucose metabolism was performed.

The Investigators hypothesis is that low circulating IGF-I and compensatory hyper-secretion of GH, in the presence of peripheral insulin excess, results in increased local IGF-I expression explaining both the deterioration in metabolic control and the increased risk for microvascular complications.

In conclusion, correction of imbalance in circulating and tissue-specific levels of IGF-I could lead to both better early metabolic control and to prevention of early diabetic complications in type 1 diabetic (T1DM) patients.

Study Design:

This is a placebo controlled crossover study of the effect of sc IGF-1 (Increlex) administration on glucose infusion rate (whole body glucose utilization) and interstitial muscle IGF-1 concentrations under euglycemic clamp conditions in T1DM adolescents and young adults (18-23 y of age). Each subject is studied twice and randomized to receive IGF-1 (120 μg/ kg, Increlex®, Ipsen) or placebo. Glucose control is optimized by CSII (Continuous Subcutaneus Insulin Infusion) for 2 days and subjects are studied after an overnight fast using a constant low rate insulin infusion to block hepatic glucose production. After a single s.c. bolus of IGF-1, the effects of IGF-1 on the peripheral glucose disposal rate will be assessed based on the rate of a variable glucose infusion. Local muscle IGF-1 measured by microdialysis will be related to the peripheral glucose disposal rate (mainly determined by muscle glucose uptake). Patients with T1DM will be studied for several reasons: 1) They are a target group for long term treatment, 2) They are IGF-I deficient and thus more likely to have a significant effect of sc IGF-I injections, 3) muscle levels may or may not be low.

The following assessments will be performed:

• Height & Weight
• Glucose utilization rate (normoinsulinemic, euglycemic clamp)
• Blood parameters: P-glucose, Growth Hormone (GH), IGF-1, Insulin Like Growth Factor Binding Proteins 1-3 (IGFBP1-3) and Glucagon
• Microdialysis IGF-1

Conditions

Type 1 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: SINGLE

Study Groups

Saline

Group Type: PLACEBO_COMPARATOR

0.9% Saline

Intervention Type: DRUG

Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection

Increlex

Group Type: ACTIVE_COMPARATOR

Increlex

Intervention Type: DRUG

Increlex 120 micrograms/kg body weight single subcutaneous injection

Interventions

Increlex

Increlex 120 micrograms/kg body weight single subcutaneous injection

Intervention Type: DRUG

0.9% Saline

Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Type 1 diabetes duration at least two years and assumed C-peptide negativity

2. Chronological age from 18 to 25 years

3. Tanner stage > 4 (Girls: Tanner B4 or more, Boys: Testis > 15 ml)

4. Levemir or Lantus as basal analogue or CSII

5. IGF-1 < -1.0 SDS and HbA1C < 73 mmol/mol with screening or within past three months

6. Written informed consent

Exclusion Criteria

1. Development of hypoglycemia that can not be controlled with increased glucose infusion-rate

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 23 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peter Bang

OTHER

Sponsor Role: lead

Responsible Party

Peter Bang

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Peter Bang, Professor

Role: PRINCIPAL_INVESTIGATOR

Karolinska University Hospital, Pediatric Endicrinology Unit, Dept of Women´s and Children´s Health

Locations

Pediatric Endocrinology Unit, Dept of Women's and Children's Health, Karolinska Institute & University Hospital

Stockholm, , Sweden

Countries

Sweden

Other Identifiers

MDIGF-1

Identifier Type: -

Identifier Source: org_study_id